Shire plc:企業資訊報告

Shire在2005∼2011年期間銷售額急速增加。有效生命週期管理策略，人類基因治療藥物領域擴大為主要因素。今後，該公司的研究開發平台將偏向初期階段產品，由於近幾年的新產品銷售，銷售成長率將會降低。

本報告提供全球處方藥市場上Shire到現在為止的業績和今後展望相關分析，企業策略·結構，產品結構·開發平台分析，財務實際成果的評估，今後1∼6年的主要藥物的銷售額等等的調查評估，並將結果概述為以下內容。

分析範圍

摘要整理

• 調查結果
• Shire處方藥銷售額預測
• Shire的財政預測
• SWOT分析

策略性考察

• 調查結果
• 新產品/核心/專利失效分析
• 策略性考察
  • 中樞神經系統(CNS)的集中度雖然已經減少，但這個治療領域今後5年將持續成為銷售額的中心
  • 利基疾病:Shire的又一個銷售額成長的支柱
  • 由於在中樞神經系統市場上與學名藥競爭，利基疾病的集中合理化

企業結構

• 調查結果
• 背景情況
• 企業結構
  • 人類基因治療
  • 特殊醫藥品
  • 再生醫療
• 企業合併·收購(收購與合併)的歷史
  • 收購與合併的策略

經營實際成果

• 調查結果
• PharmaVitae的銷售額資料和企業發表的銷售額的差異:過去6年
• 營運成本·營業利潤分析
  • 營運成本·營業利潤分析(過去6年)
  • 營運成本比率·營業利潤率分析(過去6年)
  • 營運成本比率·營業利潤率分析(今後6年)
  • 營運成本·營業利潤分析(今後6年)

附錄

圖表一覽

Abstract

Analysis of Shire's corporate strategy, marketed portfolio, pipeline potential and financial position in 2011 and to 2017.

INTRODUCTION

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

FEATURES AND BENEFITS

• Gain insight into Shire's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

HIGHLIGHTS

• Shire exhibited rapid revenue growth over 2005-11, despite a dip in sales over 2008-09 caused by generic erosion to Adderall XR. Shire's impressive performance has been driven not only by its effective lifecycle management strategy, but also by strong uptake of its Human Genetic Therapies portfolio.
• During the forecast period, Shire is expected to see a slowdown in sales growth. This is largely attributable to the absence of new product launches in the near future, given that its R&D pipeline is largely based on early-stage products.

YOUR KEY QUESTIONS ANSWERED

• Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
• Assess how successful Shire will be in diversifying its business focus and reducing its reliance on the US ADHD market
• See how Shire has developed a portfolio of products indicated for highly symptomatic diseases in an effort to build sustainable growth

SCOPE OF SHIRE ANALYSIS

• PharmaVitae Explorer database

• Analysis structure
  • Strategic Insight
  • Company Overview
  • Operating Performance Analysis

EXECUTIVE SUMMARY

• Key findings
• Shire prescription pharmaceutical sales outlook
• Shire financial outlook

• SWOT analysis
  • Weaknesses
  • Opportunities
  • Threats

STRATEGIC INSIGHT

• Key findings
• Launch/core/expiry analysis

• Strategic insight
  • Despite a declining focus in CNS, this therapy area will continue to generate the majority of sales out to 2017
  • Niche disorders to be Shire's other key area of sales growth
  • Generic competition in CNS market justifies switch in focus to niche disorders

CORPORATE STRUCTURE

• Key findings
• Background

• Corporate structure
  • Human Genetic Therapies
  • Specialty Pharmaceuticals
  • Regenerative Medicine

• M&A history
  • M&A strategy

OPERATING PERFORMANCE

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2005 - 11

• Operating costs and profit analysis
  • Operating costs and profit analysis, 2005 - 11
  • Operating cost ratio and profit margin analysis, 2005 - 11
  • Operating cost ratio and profit margin analysis, 2011 - 17
  • Operating costs and profit analysis, 2011 - 17

APPENDIX

• References
• Exchange rates

• Table: Datamonitor's established pharmaceutical company coverage, 2012
• Table: Shire - key product overview ($m), 2011 - 17
• Table: Shire's financial performance ($m), 2011 - 17
• Table: Shire's launch, core, and expiry portfolio overview ($m), 2011 - 17
• Table: The Gaucher disease market, 2012
• Table: Shire's key merger and acquisition deals, 1995-12
• Table: Total Shire sales by business unit ($m), 2005 - 11
• Table: Shire's operating revenue/cost analysis ($m), 2005 - 11
• Table: Shire's operating cost ratio analysis (percentage of total revenues), 2005 - 11
• Table: Shire's operating cost ratio analysis (percentage of total revenues), 2011 - 17
• Table: Shire's operating revenue/cost analysis ($m), 2011 - 17
• Table: Exchange rates, 2012

• Figure: The PharmaVitae Explorer
• Figure: Shire's prescription pharmaceutical performance, sales ($m) and growth rate (%), 2005 - 17
• Figure: Shire's financial performance ($m), 2005 - 17
• Figure: Shire's launch/core/expiry configuration ($m), 2011 - 17
• Figure: Shire's prescription pharmaceutical sales, by therapy area ($m), 2003 - 17
• Figure: Forecast sales of the Gaucher disease drug market ($m), 2011 - 17
• Figure: Shire's corporate structure
• Figure: Shire's operating revenue/cost analysis ($m), 2005 - 17